Literature DB >> 9738036

Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.

C J Jessup1, M A Pfaller, S A Messer, J Zhang, M Tumberland, E K Mbidde, M A Ghannoum.   

Abstract

We compared the yeast nitrogen base (YNB) broth microdilution method with the National Committee for Clinical Laboratory Standards (NCCLS) M27-A microdilution reference method for measuring the in vitro susceptibility of Cryptococcus neoformans isolates to fluconazole. A total of 149 isolates of C. neoformans var. neoformans from Ugandan AIDS patients was tested by both methods. An overall agreement of 88% between the two microdilution methods was observed. All isolates grew well in both RPMI 1640 and YNB media, and MICs could be read after 48 h of incubation by both methods. The range of fluconazole MICs obtained with the YNB method was broader than that obtained with the NCCLS method. The extended range of MICs provided by the YNB method may be of clinical value, as it appears that the clinical outcome may be better among patients infected with strains inhibited by lower concentrations of fluconazole as determined by the YNB method. The YNB method appears to be a viable option for testing C. neoformans against fluconazole.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738036      PMCID: PMC105080     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Editorial response: management of cryptococcal meningitis--have we answered all the questions?

Authors:  W G Powderly
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

3.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

4.  Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole.

Authors:  H Sanati; S A Messer; M Pfaller; M Witt; R Larsen; A Espinel-Ingroff; M Ghannoum
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 5.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).

Authors:  K J Kwon-Chung; I Polacheck; J E Bennett
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

7.  Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.

Authors:  A Casadevall; E D Spitzer; D Webb; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.

Authors:  M Pfaller; J Zhang; S Messer; M Tumberland; E Mbidde; C Jessup; M Ghannoum
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

9.  Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.

Authors:  M D Witt; R J Lewis; R A Larsen; E N Milefchik; M A Leal; R H Haubrich; J A Richie; J E Edwards; M A Ghannoum
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

10.  Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype.

Authors:  L Millon; A Manteaux; G Reboux; C Drobacheff; M Monod; T Barale; Y Michel-Briand
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

View more
  14 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens.

Authors:  Michael A Hast; Connie B Nichols; Stephanie M Armstrong; Shannon M Kelly; Homme W Hellinga; J Andrew Alspaugh; Lorena S Beese
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

3.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.

Authors:  Nelesh P Govender; Jaymati Patel; Marelize van Wyk; Tom M Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

4.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.

Authors:  Robert A Larsen; Madeline Bauer; Ann M Thomas; Alejandro Sanchez; Diane Citron; Meri Rathbun; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species.

Authors:  Arielle Butts; Parker Reitler; Andrew T Nishimoto; Christian DeJarnette; Leanna R Estredge; Tracy L Peters; Michael P Veve; P David Rogers; Glen E Palmer
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

7.  A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates.

Authors:  Sherman Chu; Lisa Long; Rania Sherif; Thomas S McCormick; Katyna Borroto-Esoda; Stephen Barat; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

8.  Two Rac paralogs regulate polarized growth in the human fungal pathogen Cryptococcus neoformans.

Authors:  Elizabeth Ripley Ballou; Kyla Selvig; Jessica L Narloch; Connie B Nichols; J Andrew Alspaugh
Journal:  Fungal Genet Biol       Date:  2013-06-05       Impact factor: 3.495

9.  Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.

Authors:  Kyle D Smith; Beatrice Achan; Kathy Huppler Hullsiek; Tami R McDonald; Laura H Okagaki; Ali A Alhadab; Andrew Akampurira; Joshua R Rhein; David B Meya; David R Boulware; Kirsten Nielsen
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.